CD38 and Miyoshi myopathy: In the present study, patients did not receive anti-CD38 antibody-based induction, and future studies will reveal long-term outcomes of high-risk MM patients, including those with 1q + , who receive quadruplet dara-based induction regimens followed by autoHCT.